Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong

Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong

Abstract Background Pembrolizumab has been shown to improve overall survival (OS) and progression free survival (PFS) compared to ipilimumab in patients with ipilimumab-naïve advanced melanoma; however, there are no published data on the cost-effectiveness for pembrolizumab compared to standard-of-c...

Full description

Bibliographic Details
Main Authors: Herbert H. Loong, Carlos K. H. Wong, Linda K. S. Leung, S. C. Tan, Jason Jen, Mary Y. K. Lee, Raquel Aguiar-Ibáñez, Jingshu Wang
Format: Article
Language:English
Published: BMC 2020-01-01
Series:Cost Effectiveness and Resource Allocation
Online Access:https://doi.org/10.1186/s12962-020-0200-9

Internet

https://doi.org/10.1186/s12962-020-0200-9

Similar Items